Abivax (ABVX) Competitors $8.88 +0.05 (+0.58%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. BEAM, IDYA, IRON, BLTE, CNTA, HRMY, ADPT, SRPT, TARS, and IMCRShould you be buying Abivax stock or one of its competitors? The main competitors of Abivax include Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Tarsus Pharmaceuticals (TARS), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Abivax vs. Its Competitors Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Sarepta Therapeutics Tarsus Pharmaceuticals Immunocore Abivax (NASDAQ:ABVX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Does the media favor ABVX or BEAM? In the previous week, Beam Therapeutics had 7 more articles in the media than Abivax. MarketBeat recorded 10 mentions for Beam Therapeutics and 3 mentions for Abivax. Abivax's average media sentiment score of 1.02 beat Beam Therapeutics' score of 0.79 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ABVX or BEAM? Abivax has higher earnings, but lower revenue than Beam Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/ABeam Therapeutics$63.52M31.00-$376.74M-$4.61-4.25 Do analysts rate ABVX or BEAM? Abivax presently has a consensus price target of $31.00, indicating a potential upside of 250.28%. Beam Therapeutics has a consensus price target of $48.75, indicating a potential upside of 148.98%. Given Abivax's higher probable upside, research analysts plainly believe Abivax is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more risk and volatility, ABVX or BEAM? Abivax has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Do insiders & institutionals believe in ABVX or BEAM? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ABVX or BEAM more profitable? Abivax has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Abivax's return on equity of 0.00% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Beam Therapeutics -609.24%-44.24%-30.97% SummaryBeam Therapeutics beats Abivax on 7 of the 13 factors compared between the two stocks. Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricAbivaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$560.46M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E RatioN/A20.2228.5719.58Price / SalesN/A293.85424.2194.37Price / CashN/A43.1536.0257.93Price / Book12.837.568.135.54Net Income-$190.71M-$55.11M$3.24B$257.73M7 Day Performance14.19%7.56%2.03%0.95%1 Month Performance26.79%11.47%8.29%10.68%1 Year Performance-35.64%0.88%28.40%15.67% Abivax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXAbivax2.2368 of 5 stars$8.85+0.2%$31.00+250.3%-35.2%$560.46MN/A0.0061News CoveragePositive NewsHigh Trading VolumeBEAMBeam Therapeutics2.2658 of 5 stars$19.18-4.1%$48.75+154.2%-21.2%$2.01B$63.52M-4.16510IDYAIDEAYA Biosciences3.5606 of 5 stars$21.16-4.3%$53.73+153.9%-43.6%$1.94B$7M-5.8980IRONDisc Medicine3.1997 of 5 stars$53.38-2.5%$96.70+81.2%+22.4%$1.90BN/A-13.6230News CoverageInsider TradeBLTEBelite Bio2.0138 of 5 stars$58.63-1.4%$96.67+64.9%+29.3%$1.89BN/A-43.1110CNTACentessa Pharmaceuticals3.2027 of 5 stars$13.62-3.2%$27.89+104.8%+53.4%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8341 of 5 stars$32.24+0.2%$53.63+66.3%+2.8%$1.85B$714.73M12.31200News CoveragePositive NewsADPTAdaptive Biotechnologies2.8726 of 5 stars$11.74-0.5%$10.57-10.0%+188.8%$1.79B$178.96M-12.23790SRPTSarepta Therapeutics4.6817 of 5 stars$17.32-5.0%$60.88+251.5%-87.4%$1.79B$1.90B-6.441,372Trending NewsTARSTarsus Pharmaceuticals1.9216 of 5 stars$39.93-3.0%$66.67+67.0%+41.1%$1.73B$182.95M-14.6350News CoveragePositive NewsAnalyst RevisionIMCRImmunocore1.431 of 5 stars$32.41-1.8%$58.89+81.7%-10.7%$1.66B$310.20M-75.37320 Related Companies and Tools Related Companies BEAM Competitors IDYA Competitors IRON Competitors BLTE Competitors CNTA Competitors HRMY Competitors ADPT Competitors SRPT Competitors TARS Competitors IMCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABVX Stock Alerts